激动剂-话题@MedSci

#激动剂#

173篇内容 | 3328人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1627826, encodeId=e82f162e8266c, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=J Urol：GnRH激动剂 VS拮抗剂在晚期前列腺癌和心血管疾病患者中的心血管发病率, objectType=article, longId=197429, objectId=877719e4295d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=877719e4295d, replyNumber=0, likeNumber=74, createdTime=2020-07-14, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=877719e4295d, moduleTitle=J Urol：GnRH激动剂 VS拮抗剂在晚期前列腺癌和心血管疾病患者中的心血管发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=877719e4295d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627825, encodeId=63c1162e82512, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=第一个也是**的GLP-1激动剂口服药物Rybelsus，再次获认可, objectType=article, longId=196867, objectId=4cbc19686e58, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cbc19686e58, replyNumber=0, likeNumber=60, createdTime=2020-07-02, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cbc19686e58, moduleTitle=第一个也是**的GLP-1激动剂口服药物Rybelsus，再次获认可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cbc19686e58)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627824, encodeId=8956162e824fe, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, objectType=article, longId=196499, objectId=fcb619649997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcb619649997, replyNumber=0, likeNumber=45, createdTime=2020-06-27, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcb619649997, moduleTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcb619649997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627823, encodeId=ce0d162e8232f, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=针对抗PD-1/PD-L1治疗后进展的黑色素瘤：G蛋白雌激素受体激动剂LNS8801获得FDA快速通道, objectType=article, longId=196199, objectId=04db19619962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04db19619962, replyNumber=0, likeNumber=49, createdTime=2020-06-22, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04db19619962, moduleTitle=针对抗PD-1/PD-L1治疗后进展的黑色素瘤：G蛋白雌激素受体激动剂LNS8801获得FDA快速通道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04db19619962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627822, encodeId=1ca5162e8220d, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JCEM：GLP-1受体激动剂治疗肥胖、多囊卵巢综合征和不孕, objectType=article, longId=194661, objectId=5fd5194661ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fd5194661ef, replyNumber=0, likeNumber=68, createdTime=2020-05-25, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fd5194661ef, moduleTitle=JCEM：GLP-1受体激动剂治疗肥胖、多囊卵巢综合征和不孕, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fd5194661ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627821, encodeId=a9f7162e821ea, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, objectType=article, longId=194316, objectId=c1c619431626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1c619431626, replyNumber=0, likeNumber=23, createdTime=2020-05-19, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1c619431626, moduleTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1c619431626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627820, encodeId=7739162e8204f, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, objectType=article, longId=193810, objectId=97c7193810df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97c7193810df, replyNumber=0, likeNumber=25, createdTime=2020-05-10, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97c7193810df, moduleTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97c7193810df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627819, encodeId=2cc5162e819b5, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JACC：KCNQ1抗体在体内可作为IKs通道的激动剂, objectType=article, longId=193393, objectId=a9ad193393a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9ad193393a0, replyNumber=0, likeNumber=67, createdTime=2020-05-04, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9ad193393a0, moduleTitle=JACC：KCNQ1抗体在体内可作为IKs通道的激动剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9ad193393a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627818, encodeId=4fff162e8183f, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=中国NMPA批准针对成年慢性肝病患者的血小板减少症药物——血小板生成素激动剂DOPTELET, objectType=article, longId=193385, objectId=69891933853e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69891933853e, replyNumber=0, likeNumber=58, createdTime=2020-05-04, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69891933853e, moduleTitle=中国NMPA批准针对成年慢性肝病患者的血小板减少症药物——血小板生成素激动剂DOPTELET, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69891933853e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627817, encodeId=2dcc162e817d5, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=3期临床新数据证明：THR-β激动剂Resmetirom可显着降低NASH患者的肝脏脂肪和纤维化程度, objectType=article, longId=192378, objectId=5c501923e835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c501923e835, replyNumber=0, likeNumber=79, createdTime=2020-04-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c501923e835, moduleTitle=3期临床新数据证明：THR-β激动剂Resmetirom可显着降低NASH患者的肝脏脂肪和纤维化程度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c501923e835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627816, encodeId=8d72162e8161f, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功, objectType=article, longId=191736, objectId=e771191e364a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e771191e364a, replyNumber=0, likeNumber=53, createdTime=2020-04-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e771191e364a, moduleTitle=A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e771191e364a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627815, encodeId=8043162e815c6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus, objectType=article, longId=191603, objectId=16ab191603bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16ab191603bc, replyNumber=0, likeNumber=55, createdTime=2020-04-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16ab191603bc, moduleTitle=欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16ab191603bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627814, encodeId=3b1f162e814ae, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=BMJ：阿片类受体激动剂疗法可降低滥用患者死亡风险, objectType=article, longId=191449, objectId=2f921914492d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f921914492d, replyNumber=0, likeNumber=65, createdTime=2020-04-06, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f921914492d, moduleTitle=BMJ：阿片类受体激动剂疗法可降低滥用患者死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f921914492d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627813, encodeId=40e1162e8133e, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=TLR9激动剂治疗实体瘤：已取得积极的临床前数据, objectType=article, longId=190855, objectId=8b5d190855e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b5d190855e3, replyNumber=0, likeNumber=75, createdTime=2020-03-27, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b5d190855e3, moduleTitle=TLR9激动剂治疗实体瘤：已取得积极的临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b5d190855e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627812, encodeId=fce8162e81247, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=FDA再次拒绝将Intarcia公司的GLP-1受体激动剂皮下渗透泵ITCA 650，用于治疗2型糖尿病, objectType=article, longId=189905, objectId=801b18990536, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=801b18990536, replyNumber=0, likeNumber=61, createdTime=2020-03-14, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=801b18990536, moduleTitle=FDA再次拒绝将Intarcia公司的GLP-1受体激动剂皮下渗透泵ITCA 650，用于治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=801b18990536)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627811, encodeId=3974162e811b2, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Shionogi宣布在英国推出血小板生成素受体激动剂Mulpleo（lusutrombopag），用于接受侵入性治疗的慢性肝病成年患者的严重血小板减少症, objectType=article, longId=189673, objectId=433d1896e3eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=433d1896e3eb, replyNumber=0, likeNumber=55, createdTime=2020-03-12, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=433d1896e3eb, moduleTitle=Shionogi宣布在英国推出血小板生成素受体激动剂Mulpleo（lusutrombopag），用于接受侵入性治疗的慢性肝病成年患者的严重血小板减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=433d1896e3eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627810, encodeId=d537162e81021, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Zydus Cadila的PPAR激动剂saroglitazar在印度获批，用于治疗非酒精性脂肪性肝炎, objectType=article, longId=189572, objectId=17961895e2f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17961895e2f5, replyNumber=0, likeNumber=67, createdTime=2020-03-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17961895e2f5, moduleTitle=Zydus Cadila的PPAR激动剂saroglitazar在印度获批，用于治疗非酒精性脂肪性肝炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17961895e2f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627809, encodeId=51f2162e80939, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=NICE推荐将血小板生成素受体激动剂Doptelet用于肝病手术前使用, objectType=article, longId=189454, objectId=0976189454ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0976189454ff, replyNumber=0, likeNumber=85, createdTime=2020-03-07, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0976189454ff, moduleTitle=NICE推荐将血小板生成素受体激动剂Doptelet用于肝病手术前使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0976189454ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627808, encodeId=a624162e80814, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险, objectType=article, longId=188799, objectId=77e1188e9962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77e1188e9962, replyNumber=0, likeNumber=63, createdTime=2020-02-27, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77e1188e9962, moduleTitle=礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77e1188e9962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627807, encodeId=95bb162e807fc, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=抗CD27激动剂MK-5890治疗非小细胞肺癌, objectType=article, longId=187675, objectId=702918e675bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=702918e675bf, replyNumber=0, likeNumber=68, createdTime=2020-02-09, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=702918e675bf, moduleTitle=抗CD27激动剂MK-5890治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=702918e675bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激动剂

2020-05-29

一叶知秋 (审核中...)

前往app查看评论内容

#激动剂#

J Urol：GnRH激动剂 VS拮抗剂在晚期前列腺癌和心血管疾病患者中的心血管发病率

2020-07-14

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

第一个也是**的GLP-1激动剂口服药物Rybelsus，再次获认可

2020-07-02

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用

2020-06-27

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

针对抗PD-1/PD-L1治疗后进展的黑色素瘤：G蛋白雌激素受体激动剂LNS8801获得FDA快速通道

2020-06-22

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JCEM：GLP-1受体激动剂治疗肥胖、多囊卵巢综合征和不孕

2020-05-25

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功

2020-05-19

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力

2020-05-10

仁者大医 (审核中...)

前往app查看评论内容

#激动剂#

JACC：KCNQ1抗体在体内可作为IKs通道的激动剂

2020-05-04

仁者大医 (审核中...)

前往app查看评论内容

#激动剂#

中国NMPA批准针对成年慢性肝病患者的血小板减少症药物——血小板生成素激动剂DOPTELET

2020-05-04

仁者大医 (审核中...)

前往app查看评论内容

#激动剂#

3期临床新数据证明：THR-β激动剂Resmetirom可显着降低NASH患者的肝脏脂肪和纤维化程度

2020-04-17

仁者大医 (审核中...)

前往app查看评论内容

#激动剂#

A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功

2020-04-10

仁者大医 (审核中...)

前往app查看评论内容

#激动剂#

欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus

2020-04-08

仁者大医 (审核中...)

前往app查看评论内容

#激动剂#

BMJ：阿片类受体激动剂疗法可降低滥用患者死亡风险

2020-04-06

仁者大医 (审核中...)

前往app查看评论内容

#激动剂#

TLR9激动剂治疗实体瘤：已取得积极的临床前数据

2020-03-27

仁心济世 (审核中...)

前往app查看评论内容

#激动剂#

FDA再次拒绝将Intarcia公司的GLP-1受体激动剂皮下渗透泵ITCA 650，用于治疗2型糖尿病

2020-03-14

仁者大医 (审核中...)

前往app查看评论内容

#激动剂#

Shionogi宣布在英国推出血小板生成素受体激动剂Mulpleo（lusutrombopag），用于接受侵入性治疗的慢性肝病成年患者的严重血小板减少症

2020-03-12

仁者大医 (审核中...)

前往app查看评论内容

#激动剂#

Zydus Cadila的PPAR激动剂saroglitazar在印度获批，用于治疗非酒精性脂肪性肝炎

2020-03-10

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

NICE推荐将血小板生成素受体激动剂Doptelet用于肝病手术前使用

2020-03-07

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险

2020-02-27

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

抗CD27激动剂MK-5890治疗非小细胞肺癌

2020-02-09

科室
- - 订阅+
  - 更多科室
工具
服务